From GlobeNewswire: 2024-06-04 16:15:00

HeartSciences announced compliance with Nasdaq bid price requirement, canceling the scheduled hearing. The company focuses on AI technology to enhance ECGs for the early detection of heart disease. Their flagship product, MyoVista® wavECG™, aims to revolutionize cardiac screening by providing diagnostic information on cardiac dysfunction and conventional ECG data in one test. With a commitment to improving healthcare globally, HeartSciences aims to make AI-ECG solutions available on a cloud-based platform or their proprietary device. Investors should note potential risks outlined in regulatory filings. For more information, visit HeartSciences’ website or contact Gene Gephart or Vivian Cervantes for inquiries.



Read more at GlobeNewswire: HeartSciences Regains Compliance with Nasdaq Listing